168 related articles for article (PubMed ID: 31029573)
1. Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis.
Yu T; Shin IS; Yoon WS; Rim CH
Clin Lung Cancer; 2019 Jul; 20(4):e452-e462. PubMed ID: 31029573
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
6. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Rim CH; Kim HJ; Seong J
Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
8. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer.
Tateishi Y; Takeda A; Horita N; Tsurugai Y; Eriguchi T; Kibe Y; Sanuki N; Kaneko T
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):143-151. PubMed ID: 33891980
[TBL] [Abstract][Full Text] [Related]
10. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Lee P; Loo BW; Biswas T; Ding GX; El Naqa IM; Jackson A; Kong FM; LaCouture T; Miften M; Solberg T; Tome WA; Tai A; Yorke E; Li XA
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):160-171. PubMed ID: 30954520
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.
Cummings MA; Ma SJ; Hermann G; Serra L; Syed Y; Malhotra HK; Chen Y; Milano MT; Gomez-Suescun JA; Singh DP; Singh AK
Clin Lung Cancer; 2018 Nov; 19(6):511-517. PubMed ID: 30131257
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution.
Abreu CECV; Moraes FY; Miranda FA; Siqueira GSM; Gadia R; Haddad CK; Carvalho HA
J Glob Oncol; 2018 Jul; 4():1-8. PubMed ID: 30085881
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
[No Abstract] [Full Text] [Related]
14. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
Bezjak A; Paulus R; Gaspar LE; Timmerman RD; Straube WL; Ryan WF; Garces YI; Pu AT; Singh AK; Videtic GM; McGarry RC; Iyengar P; Pantarotto JR; Urbanic JJ; Sun AY; Daly ME; Grills IS; Sperduto P; Normolle DP; Bradley JD; Choy H
J Clin Oncol; 2019 May; 37(15):1316-1325. PubMed ID: 30943123
[TBL] [Abstract][Full Text] [Related]
15. Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis.
Rim CH; Kim Y; Kim CY; Yoon WS; Yang DS
Int J Radiat Biol; 2019 Mar; 95(3):329-337. PubMed ID: 30676182
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
[TBL] [Abstract][Full Text] [Related]
18. Should stereotactic body radiotherapy doses be adjusted according to tumor size in early-stage non-small-cell lung cancer? A systematic review and meta-analysis.
Luo H; Cui Y; Song H; Mao R; Gao Q; Ge H
Future Oncol; 2019 Sep; 15(26):3071-3079. PubMed ID: 31426674
[No Abstract] [Full Text] [Related]
19. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
20. Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis.
Ma SJ; Cummings M; Serra LM; Syed YA; Hermann GM; Chen Y; Milano MT; Singh AK; Gomez-Suescun JA; Singh DP
Clin Lung Cancer; 2018 May; 19(3):e297-e302. PubMed ID: 29254649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
